Ditophal

Ditophal is an orally effective thiol ester compound used as an anti-tuberculosis and anti-leprosy agent. It is effective against Mycobacterium tuberculosis infections, both subcutaneous and intracerebral, in guinea pigs, including strains resistant to isoniazid. Ditophal alters the staining properties of Mycobacterium leprae, reducing the bacterial index of leprosy. At high doses, subcutaneous administration in guinea pigs can cause ulcers at the injection site. Ditophal is utilized in research on tuberculosis and leprosy.

Ditophal, when administered orally at doses of 100-200 mg/kg twice daily for 90 days, reduces the severity scores of tuberculosis in organs and extends the survival time of guinea pigs infected subcutaneously with Mycobacterium tuberculosis. Similarly, subcutaneous injection of Ditophal at 10-50 mg/kg, daily or weekly for 120 days, achieves a comparable effect. Additionally, oral administration of Ditophal at 100-200 mg/kg twice a day over 4 weeks prolongs the average survival time of guinea pigs with intracranial Mycobacterium tuberculosis infections, with the 100 mg/kg group reaching an average survival of 35.0 days.